Table 7.
Primary pooled analysis for active forms of vitamin D and the prevention of falls
| Study (daily dose of vitamin D) | Number of participants | Number of fallers/total treated | Number of fallers/total control | Effect relative risk | Lower 95% CI | Upper 95% CI | Q test P value | I2 | Fall reduction |
|---|---|---|---|---|---|---|---|---|---|
| Dukas et al, 2004w16 (1α-hydroxyvitamin D3) | 378 | 40/192 | 46/186 | 0.84 | 0.58 | 1.22 | — | — | — |
| Gallagher et al, 2001w17 (1,25-dihydroxyvitamin D3) | 246 | 59/123 | 78/123 | 0.76 | 0.60 | 0.95 | — | — | — |
| Pooled primary analysis (w16,w17) | 624 | 99/315 | 124/309 | 0.78 | 0.64 | 0.94 | 0.63 | 0% | -22% |
Q test: P<0.100 indicates heterogeneity.
I2 estimates above 25% are considered to represent modest heterogeneity, and values above 50% represent large heterogeneity beyond chance.